Covid-19 roundup: GSK CEO Emma Walmsley — some trial delays, but we’re limiting the damage — so far; Trump planning ‘Warp Speed’ vaccine plan
All the major pharmas are wrestling with the Covid-19 outbreak in one way or another. For some, like Eli Lilly, the executive teams have delayed patient recruitment on a wide number of trials, which will likely have a deep impact on development plans — particularly at the earlier stages.
But over at GlaxoSmithKline, the emphasis has been on finding ways to keep its operations on track — including R&D. Here’s a lengthy set of remarks from Emma Walmsley’s Q1 review, which help encapsulate both the effects of the outbreak and their strategy for dealing with it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.